Knight Common Stock Total Equity vs Net Debt Analysis
GUD Stock | CAD 5.86 0.12 2.09% |
Knight Therapeutics financial indicator trend analysis is infinitely more than just investigating Knight Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Knight Therapeutics is a good investment. Please check the relationship between Knight Therapeutics Common Stock Total Equity and its Net Debt accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Knight Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Common Stock Total Equity vs Net Debt
Common Stock Total Equity vs Net Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Knight Therapeutics Common Stock Total Equity account and Net Debt. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Knight Therapeutics' Common Stock Total Equity and Net Debt is -0.44. Overlapping area represents the amount of variation of Common Stock Total Equity that can explain the historical movement of Net Debt in the same time period over historical financial statements of Knight Therapeutics, assuming nothing else is changed. The correlation between historical values of Knight Therapeutics' Common Stock Total Equity and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Total Equity of Knight Therapeutics are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Common Stock Total Equity i.e., Knight Therapeutics' Common Stock Total Equity and Net Debt go up and down completely randomly.
Correlation Coefficient | -0.44 |
Relationship Direction | Negative |
Relationship Strength | Very Weak |
Common Stock Total Equity
The total value of common stock equity held by shareholders, representing their ownership interest in the company.Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Most indicators from Knight Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Knight Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Knight Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Knight Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 14th of June 2024, Enterprise Value Over EBITDA is likely to grow to 10.50, though Tax Provision is likely to grow to (4.9 M).
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 3.6M | 6.6M | 12.5M | 9.4M | Depreciation And Amortization | 47.9M | 62.6M | 72.0M | 75.6M |
Knight Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Knight Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Knight Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.3B | 1.0B | 991.9M | 1.1B | 945.5M | 952.1M | |
Total Stockholder Equity | 810.7M | 886.2M | 842.0M | 825.9M | 746.9M | 823.4M | |
Net Debt | (107.1M) | (173.4M) | (45.0M) | 6.0M | 3.1M | 3.3M | |
Cash | 169.3M | 229.6M | 86.0M | 71.7M | 58.8M | 55.8M | |
Cash And Short Term Investments | 430.6M | 411.3M | 163.0M | 191.2M | 172.1M | 163.5M | |
Common Stock Total Equity | 761.5M | 761.8M | 723.8M | 694.4M | 798.5M | 616.3M | |
Common Stock Shares Outstanding | 140.1M | 132.0M | 124.5M | 114.9M | 101.2M | 123.2M | |
Total Current Assets | 698.2M | 554.6M | 307.3M | 395.6M | 365.1M | 556.5M | |
Common Stock | 723.8M | 694.4M | 628.9M | 599.1M | 688.9M | 628.1M | |
Other Current Liab | 225.6M | 15.9M | 11.7M | 15.0M | 1.0M | 993.7K | |
Total Current Liabilities | 350.8M | 114.1M | 105.3M | 141.3M | 114.0M | 96.9M | |
Net Tangible Assets | 1.0B | 549.1M | 652.0M | 416.3M | 374.7M | 569.1M | |
Property Plant And Equipment Net | 29.0M | 26.2M | 29.9M | 22.6M | 17.9M | 14.0M | |
Current Deferred Revenue | 282K | 183K | 39.9M | 14.6M | 16.8M | 8.9M | |
Retained Earnings | 52.2M | 174.5M | 191.6M | 161.8M | 150.9M | 178.6M | |
Accounts Payable | 72.8M | 44.5M | 65.3M | 106.1M | 85.4M | 89.6M | |
Non Current Assets Total | 607.1M | 485.0M | 684.6M | 659.2M | 580.4M | 435.2M | |
Other Assets | 152.0M | 75.5M | 57.1M | 15.6M | 17.9M | 17.0M | |
Net Receivables | 111.7M | 82.0M | 67.4M | 110.2M | 88.7M | 52.7M | |
Short Term Investments | 261.3M | 181.7M | 77.0M | 119.5M | 111.4M | 174.0M | |
Liabilities And Stockholders Equity | 1.3B | 1.0B | 991.9M | 1.1B | 1.2B | 1.0B | |
Inventory | 70.9M | 56.5M | 72.4M | 92.5M | 91.8M | 96.4M | |
Other Current Assets | 85.0M | 4.8M | 4.5M | 1.7M | 2.0M | 1.9M | |
Other Stockholder Equity | 17.2M | 18.8M | 21.9M | 23.8M | 27.3M | 15.8M | |
Total Liab | 390.2M | 153.4M | 149.9M | 229.0M | 198.6M | 130.2M | |
Long Term Investments | 259.7M | 174.8M | 179.0M | 158.0M | 120.0M | 183.4M | |
Property Plant And Equipment Gross | 29.0M | 26.2M | 41.0M | 56.1M | 39.5M | 21.3M | |
Accumulated Other Comprehensive Income | 17.4M | (1.5M) | (376K) | 41.3M | 37.1M | 39.0M | |
Short Term Debt | 52.3M | 53.6M | 28.3M | 20.3M | 18.2M | 17.3M | |
Intangible Assets | 173.4M | 156.5M | 350.3M | 338.8M | 290.0M | 149.3M | |
Property Plant Equipment | 29.0M | 26.2M | 29.9M | 22.6M | 26.0M | 13.4M | |
Other Liab | 4.6M | 29.6M | 36.8M | 31.9M | 36.7M | 38.5M | |
Non Current Liabilities Total | 39.4M | 39.4M | 44.6M | 87.7M | 84.6M | 88.8M | |
Non Currrent Assets Other | 52.7M | 47.3M | 47.9M | 48.2M | 43.4M | 70.6M | |
Long Term Debt Total | 9.8M | 2.5M | 12.7M | 57.4M | 66.1M | 69.4M | |
Capital Surpluse | 16.5M | 18.7M | 21.8M | 23.7M | 27.2M | 18.3M | |
Cash And Equivalents | 5.3M | 2.6M | 9.0M | 302K | 271.8K | 258.2K | |
Net Invested Capital | 866.3M | 938.0M | 877.9M | 895.9M | 808.7M | 732.4M | |
Net Working Capital | 270.7M | 438.0M | 199.7M | 254.3M | 251.1M | 331.3M | |
Capital Stock | 723.8M | 694.4M | 628.9M | 599.1M | 540.0M | 526.4M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Knight Stock
Balance Sheet is a snapshot of the financial position of Knight Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Knight Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Knight Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Knight currently owns. An asset can also be divided into two categories, current and non-current.